GuiDeCode
Calcs › ◉ Hematology / Oncology

Follicular Lymphoma International Prognostic Index (FLIPI)

Five-factor prognostic scoring system for follicular lymphoma predicting overall survival

Calculator

Loading calculator…

Why use it

Follicular lymphoma is an indolent but incurable B-cell lymphoma with a highly variable clinical course — some patients survive decades with minimal treatment while others experience rapid progression. FLIPI enables risk stratification at diagnosis to guide treatment intensity, clinical trial eligibility, frequency of surveillance, and patient counseling. The GELF criteria are used alongside FLIPI to determine whether treatment is immediately needed, while FLIPI guides selection of therapy intensity.

About

The Follicular Lymphoma International Prognostic Index (FLIPI) is the most widely validated prognostic scoring system for follicular lymphoma (FL), developed from a retrospective international cohort of 4167 patients by Solal-Céligny and colleagues. It identifies five independent adverse prognostic factors: age >60 years, Ann Arbor stage III–IV, elevated serum LDH, hemoglobin <12 g/dL, and more than four nodal areas involved. Each adverse factor scores 1 point (total 0–5), stratifying patients into three risk groups: low (0–1), intermediate (2), and high (≥3). In the original cohort, 10-year overall survival was approximately 71%, 51%, and 36% for low, intermediate, and high-risk groups respectively. Although derived in the pre-rituximab era, FLIPI remains relevant in the current immunochemotherapy era and was updated by the FLIPI-2 (using beta-2 microglobulin, bone marrow involvement, longest diameter of largest node, hemoglobin, and age). The original FLIPI is more widely used in clinical practice due to its simplicity.

When to use

  • At diagnosis of follicular lymphoma to determine prognosis and guide management decisions
  • Selecting patients for clinical trial stratification
  • Counseling patients about expected disease course and treatment intensity
  • Reassessing prognosis after transformation to aggressive lymphoma
  • Guiding frequency of surveillance imaging and follow-up schedules
  • Determining eligibility for maintenance rituximab or obinutuzumab-based strategies

Formula

FLIPI Score (0–5 points; 1 point each): Age > 60 years: +1 point Ann Arbor Stage III or IV: +1 point Serum LDH above upper limit of normal: +1 point Hemoglobin < 12 g/dL (<7.45 mmol/L): +1 point More than 4 nodal areas involved: +1 point Risk Groups: 0–1: Low risk 2: Intermediate risk ≥3: High risk Historical 10-year OS (pre-rituximab): Low: ~71% Int: ~51% High: ~36%

Pearls & pitfalls

  • FLIPI does NOT determine WHEN to treat — the GELF (Groupe d'Etude des Lymphomes Folliculaires) criteria determine treatment urgency. FLIPI determines which therapy and how aggressively.
  • Bone marrow involvement (common in FL) does NOT independently affect FLIPI score — it is incorporated into Ann Arbor staging (Stage IV).
  • The FLIPI-2 (2009) uses different variables (beta-2 microglobulin, BM involvement, longest node diameter, Hb, age) and was designed for the rituximab era, but is less commonly used than the original FLIPI in routine practice.
  • Transformation to diffuse large B-cell lymphoma (DLBCL) completely changes prognosis — FLIPI does NOT apply after histological transformation.
  • High FLIPI (≥3) at diagnosis is associated with earlier requirement for treatment and shorter time to first progression after first-line therapy.
  • Despite its derivation in the pre-rituximab era, the FLIPI prognostic groups remain discriminatory with modern immunochemotherapy (OS at 5 years approximately 90%, 80%, 67% for low, intermediate, high risk with BR or R-CHOP).
  • Four nodal areas: The FLIPI uses 17 defined nodal regions (similar to Cotswolds modification). More than 4 nodal areas = 1 point.
  • LDH: Use the institutional upper limit of normal — any elevation above normal = 1 point.

Next steps

Low Risk (FLIPI 0–1): Indolent course expected. If asymptomatic and low tumor burden (GELF criteria absent): active surveillance ("watchful waiting") is appropriate. First-line therapy when needed: rituximab monotherapy or bendamustine-rituximab. 10-year OS ~71%. Intermediate Risk (FLIPI 2): Mixed outcomes. Treatment decision based on GELF criteria and symptoms. BR or R-CHOP standard when treatment needed. 10-year OS ~51%. High Risk (FLIPI ≥3): More aggressive course. Earlier treatment initiation generally favored. Consider enrollment in clinical trials. 10-year OS ~36% in pre-rituximab data (better in modern era with obinutuzumab-containing regimens).

Evidence

Solal-Céligny P et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265. PMID:15126323. Cohort: 4167 patients. Validated in multiple subsequent cohorts. Federico M et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555-4562. PMID:19652063.

References

  1. Solal-Céligny P et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265. — link
  2. Federico M et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555-4562. — link
  3. Marcus R et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331-1344. — link